All In Biotech

Drug Trial Radar · NCT06917690

A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa

Multi-centeR, Open-label Study to EValuate the Safety, Efficacy, and Pharmacokinetics of FIlsuVEz (Oleogel-S10) in Japanese Subjects With Epidermolysis Bullosa (REVIVE)

Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

6

Planned (sponsor's estimate)

Start

Apr 18, 2025

Primary completion

Mar 2026

Study completion Sep 2029

Sponsor

Lead sponsor
Chiesi Farmaceutici S.p.A.Industry
Sponsor type
Industry
First posted
Apr 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 21 days
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if Oleogel-S10 gel works to treat skin wounds from two types of inherited epidermolysis bullosa (EB): junctional EB (JEB) or dystrophic EB (DEB) in the Japanese population. Children and adults may participate. The trial also looks at the safety of Oleogel-S10 gel. The main questions it will answer are: * Does Oleogel-S10 gel close wounds from JEB or DEB within 45 days or reduce the size of the wounds? * Are there any medical problems when using Oleogel-S10 gel? * How much of the drug ends up in your blood? The study has 2 parts. In Part 1, participants will: * Apply Oleogel-S10 gel to the EB wound dressings at least once every 4 days for 45 days. * Visit the clinic once every 2 weeks for checkups and tests. If participants complete Part 1, they may participate in Part 2 if they choose to. In Part 2, participants will continue to receive Oleogel-S10 gel until the product is available to buy in Japan or until the trial is stopped by the company.

Conditions

  • Epidermolysis Bullosa
  • Junctional Epidermolysis Bullosa
  • Epidermolysis Bullosa, Dystrophic
  • Epidermolysis Bullosa, Junctional
  • Skin Abnormalities
  • Connective Tissue Disease
  • Collagen Diseases
  • Skin Diseases
  • Genetic Diseases, Inborn
  • Congenital Abnormalities

Interventions

  • Oleogel-S10Drug

    Topical gel

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the efficacy of Oleogel-S10 in Part ITime frame: Enrollment to 45 days

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Fukuoka Children's Hospital - Dermatology

    Fukuoka, Japan · Recruiting

  • Kurume University Hospital

    Fukuoka, Japan · Recruiting

  • Kobe University Hospital

    Kobe, Japan · Recruiting

  • Niigata University Medical and Dental Hospital

    Niigata, Japan · Recruiting

  • Toho University Omori Medical Center

    Ōta-ku, Japan · Recruiting

  • Hokkaido University Hospital

    Sapporo, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.